SevenBridge Financial Group LLC Grows Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

SevenBridge Financial Group LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,076 shares of the company’s stock after purchasing an additional 425 shares during the quarter. SevenBridge Financial Group LLC’s holdings in CRISPR Therapeutics were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of CRSP. Global Trust Asset Management LLC increased its holdings in shares of CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC increased its holdings in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC raised its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in CRISPR Therapeutics in the 2nd quarter worth about $35,000. Finally, Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics during the 3rd quarter valued at about $43,000. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 35,382 shares of company stock valued at $1,917,679 over the last 90 days. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

CRSP opened at $47.88 on Monday. The company has a 50 day simple moving average of $47.98 and a two-hundred day simple moving average of $51.74. The firm has a market cap of $4.09 billion, a P/E ratio of -16.92 and a beta of 1.67. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the firm posted ($1.41) EPS. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of research analyst reports. Chardan Capital reduced their price target on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Stifel Nicolaus dropped their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Truist Financial reduced their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and an average target price of $74.94.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.